Dina Simkin

Dina Simkin, Professor of Neurology at Northwestern University, joins us in this episode of CRISPR Cuts. Dr. Simkin talks about her path to becoming a researcher, art, and the importance of patient and isogenic iPSC models to study genetically linked forms of epilepsies.

Dina Simkin, Professor of Neurology at Northwestern University, joins us in this episode of CRISPR Cuts. Dr. Simkin talks about her path to becoming a researcher, art, and the importance of patient and isogenic iPSC models to study genetically linked forms of epilepsies.

Dina Simkin Breaks Down Epilepsy Cell Modeling

Dr. Sunil Sharma and Dr. Raffaella Soldi of the Translational Genomics Research Institute chat about using CRISPR arrayed screens to identify novel drug targets for Ewing's Sarcoma, outlooks for the future of cancer therapies, and the Arizona heat.

Dr. Sunil Sharma and Dr. Raffaella Soldi of the Translational Genomics Research Institute chat about using CRISPR arrayed screens to identify novel drug targets for Ewing's Sarcoma, outlooks for the future of cancer therapies, and the Arizona heat.

Sunil Sharma and Raffaella Soldi Talk CRISPR For Unbiased Drug Screening for Rare Pediatric Cancers

Professor Stephanie Cherqui, UCSD, has worked on the development of cell therapies for two rare genetic diseases, cystinosis and Friedreich’s ataxia. In this interview, Dr. Cherqui chats about her experience working on rare diseases, developing a CRISPR-edited therapy for Friedreich's ataxia, navigating regulatory challenges in cell and gene therapies, and more.

<a href="https://medschool.ucsd.edu/som/pediatrics/research/labs/cherqui/Pages/default.aspx" rel="nofollow" target="_blank">Professor Stephanie Cherqui,</a> UCSD, has worked on the development of cell therapies for two rare genetic diseases, cystinosis and Friedreich’s ataxia. In this interview, Dr. Cherqui chats about her experience working on rare diseases, developing a CRISPR-edited therapy for Friedreich's ataxia, navigating regulatory challenges in cell and gene therapies, and more.

Stephanie Cherqui Discusses Clinical Development of CRISPR Therapies for Rare Diseases

Tune in to hear Christian Groendahl, CEO of SNIPR Biome, talk about CRISPR editing in prokaryotes, their novel E. coli-targeting CRISPR therapy trials, and his experiences and vision leading a start up.

Tune in to hear Christian Groendahl, CEO of SNIPR Biome, talk about CRISPR editing in prokaryotes, their novel E. coli-targeting CRISPR therapy trials, and his experiences and vision leading a start up.

Christian Groendahl On Pioneering a CRISPR-based Microbial Gene Therapy

In this episode, Bryan Dechairo, CEO of Sherlock Biosciences, talks about the impact of technology advances in the field of CRISPR diagnostics, his experiences leading Sherlock Biosciences, and his team’s mission of accessibility. 

In this episode, Bryan Dechairo, CEO of Sherlock Biosciences, talks about the impact of technology advances in the field of CRISPR diagnostics, his experiences leading Sherlock Biosciences, and his team’s mission of accessibility.

Bryan Dechairo Envisions an Accessible Future for CRISPR Diagnostics

Ayal Hendel

Dr. Ayal Hendel, a genome-editing pioneer and group leader at Bar Ilan University in Israel, was one of the first researchers to use modified synthetic sgRNA to edit primary cells with CRISPR. In this episode, Dr. Hendel shares his perspectives on the recent CRISPR advancements and his work on the bubble boy disease.

Dr. Ayal Hendel, a genome-editing pioneer and group leader at Bar Ilan University in Israel, was one of the first researchers to use modified synthetic sgRNA to edit primary cells with CRISPR. In this episode, Dr. Hendel shares his perspectives on the recent CRISPR advancements and his work on the bubble boy disease.

Ayal Hendel Talks About CRISPR in Bubble Boy Disease

Jimi Olaghere

Jimi has dealt with sickle cell disease, a genetic disorder with serious implications, his entire life. Undergoing a CRISPR gene editing trial turned his hope for a cure into reality with promising results from the early phases. Tune in to learn about Jimi's journey in this episode. 

Jimi has dealt with sickle cell disease, a genetic disorder with serious implications, his entire life. Undergoing a CRISPR gene editing trial turned his hope for a cure into reality with promising results from the early phases. Tune in to learn about Jimi's journey in this episode.

Jimi Olaghere Opens up About His Sickle Cell Disease and CRISPR Trial

TJ Cradick, Chief Scientific Officer at Excision Bio, discusses their CRISPR HIV therapy that recently proceeded into clinical trials in this episode and their ongoing work on other viral diseases. 

TJ Cradick, Chief Scientific Officer at Excision Bio, discusses their CRISPR HIV therapy that recently proceeded into clinical trials in this episode and their ongoing work on other viral diseases.

TJ Cradick Speaks About Their HIV CRISPR Therapy in Trials

Bryce Olson

After being diagnosed with aggressive prostate cancer, Bryce Olson quickly learned the science behind it and has leveraged NGS to understand his tumor genomics and find opportunities in personalized therapies. Hear the patient perspective for the first time on our podcast through Bryce's narration of his experience and pursuit of next generation cell and gene therapies. 

After being diagnosed with aggressive prostate cancer, Bryce Olson quickly learned the science behind it and has leveraged NGS to understand his tumor genomics and find opportunities in personalized therapies. Hear the patient perspective for the first time on our podcast through Bryce's narration of his experience and pursuit of next generation cell and gene therapies.

Bryce Olson Relays His Experience on Personalized Therapies for Cancer Patients

Neville Sanjana

In this collaboration episode with NEB, we interview Dr. Neville Sanjana, a core faculty member at the New York Genome Center, about his recent publication in which chemically modified guide RNAs were used to enhance CRISPR-Cas13 knockdown in human cells.

In this collaboration episode with NEB, we interview Dr. Neville Sanjana, a core faculty member at the New York Genome Center, about his recent publication in which chemically modified guide RNAs were used to enhance CRISPR-Cas13 knockdown in human cells.

Neville Sanjana Discusses Ways to Enhance CRISPR-Cas13 Knockdown in Human Cells

Welcome to the CRISPR revolution. Take a break and join us as we guide conversations with an expert CRISPR cast about this cutting-edge science.

In this episode, we chat with Dr. Kiana Aran, the CSO of Cardea Bio and associate professor at Keck Graduate Institute, who recently won the Nature Research Award for Inspiring Women in Science. Dr. Aran talks about her experience being a nominee and award winner, her early days and scientific journey, and the launch of her new non-profit, Aran Nebula.

In this episode, we chat with Dr. Kiana Aran, the CSO of Cardea Bio and associate professor at Keck Graduate Institute, who recently won the Nature Research Award for Inspiring Women in Science. Dr. Aran talks about her experience being a nominee and award winner, her early days and scientific journey, and the launch of her new non-profit, Aran Nebula.

Kiana Aran Chats About her Nature Award and New Non-Profit

We chatted with six female leaders in the CRISPR—Alison van Eenennaam, Ph.D., Kiana Aran, Christina Trojel-Hansen, Ph.D., Laura Lambert, Ph.D., Elena Miñones Moyano, Ph.D., and Samantha Maragh, Ph.D.— about their professional journeys.  Tune in to this episode for a candid and honest discussion on a broad range of topics, including their experiences as women of color, life as working moms, adjusting in male-dominated fields, experiences being part of the LGBTQIA community, and the role of mentors in professional development.

We chatted with six female leaders in the CRISPR—Alison van Eenennaam, Ph.D., Kiana Aran, Christina Trojel-Hansen, Ph.D., Laura Lambert, Ph.D., Elena Miñones Moyano, Ph.D., and Samantha Maragh, Ph.D.— about their professional journeys.  Tune in to this episode for a candid and honest discussion on a broad range of topics, including their experiences as women of color, life as working moms, adjusting in male-dominated fields, experiences being part of the LGBTQIA community, and the role of mentors in professional development.

6 Women CRISPR Leaders Get Candid About Their Journeys to the Top

Jesse Boehm

In this CRISPR Cuts episode, Dr. Jesse Boehm, the Chief Scientific Officer of the Break Through Cancer Foundation and principal investigator at the Broad Institute, talks about his work on rare cancers. He also covers how CRISPR technology is transforming cancer research.

In this CRISPR Cuts episode, Dr. Jesse Boehm, the Chief Scientific Officer of the Break Through Cancer Foundation and principal investigator at the Broad Institute, talks about his work on rare cancers. He also covers how CRISPR technology is transforming cancer research.

Jesse Boehm Discusses Tackling Rare Cancers Using CRISPR

The Inducible Pluripotent Stem Cell Neurodegeneration Initiative (iNDI), an NIH effort, aims to standardize disease models for Alzheimer’s and related dementias. Hear the principal contributors, Dr. Michael E. Ward and Dr. Mark R. Cookson, scientists at the NIH, talk about the inception of the iNDI project, the challenges and opportunities, and the future of neurodegenerative research. 

The Inducible Pluripotent Stem Cell Neurodegeneration Initiative (iNDI), an NIH effort, aims to standardize disease models for Alzheimer’s and related dementias. Hear the principal contributors, Dr. Michael E. Ward and Dr. Mark R. Cookson, scientists at the NIH, talk about the inception of the iNDI project, the challenges and opportunities, and the future of neurodegenerative research.

NIH Scientists Discuss the iNDI Project for Alzheimer's Disease Modeling

Joe Miano

Prime editing is a new genome engineering tool that emerged just a couple of years back. Right from the get-go, this technology made waves as a potential alternative to CRISPR. Now, the first comparative study in mice is out. Dr. Joe Miano, Professor at the Augusta University in Georgia, talks about their collaborative work comparing traditional CRISPR-mediated homology-directed repair with prime editing in mice. 

Prime editing is a new genome engineering tool that emerged just a couple of years back. Right from the get-go, this technology made waves as a potential alternative to CRISPR. Now, the first comparative study in mice is out. Dr. Joe Miano, Professor at the Augusta University in Georgia, talks about their collaborative work comparing traditional CRISPR-mediated homology-directed repair with prime editing in mice.

Joe Miano Talks About Prime Editing in Mice

Kevin Davies

Kevin Davies, the executive editor of The CRISPR Journal, has closely watched the genetics space evolve over the last decades. His expertise and experience were the perfect foundation for his latest book "Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing." In this episode, Kevin discusses his motivation for the book, along with some behind-the-scenes stories when writing this timely literature piece.

Kevin Davies, the executive editor of The CRISPR Journal, has closely watched the genetics space evolve over the last decades. His expertise and experience were the perfect foundation for his latest book "Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing." In this episode, Kevin discusses his motivation for the book, along with some behind-the-scenes stories when writing this timely literature piece.

Kevin Davies Chats About His Latest Book "Editing Humanity"

In this episode, Michael Friend, CEO of Minority Coalition for Precision Medicine, discusses the lack of diversity in genome editing field and covers potential solutions for ensuring an inclusive future, particularly for black scientists.

In this episode, Michael Friend, CEO of Minority Coalition for Precision Medicine, discusses the lack of diversity in genome editing field and covers potential solutions for ensuring an inclusive future, particularly for black scientists.

Michael Friend Advocates For Diversity in CRISPR

Paul Dabrowski

Robert Deans

In this episode, Paul Dabrowski, CEO of Synthego, and Robert Deans, CSO of Synthego, discuss the CRISPR silver linings of 2020 and predict the directions and milestones for gene editing in 2021. 

In this episode, Paul Dabrowski, CEO of Synthego, and Robert Deans, CSO of Synthego, discuss the CRISPR silver linings of 2020 and predict the directions and milestones for gene editing in 2021.

CRISPR Forecast 2021 with Paul Dabrowski and Robert Deans

Hamid Ghanadaan

The COVID-19 pandemic is a unique situation for lab scientists, many of whose work has come to a standstill. Hamid Ghanadaan, CEO of Linus, discusses the impact of COVID-19 on science and the next steps for scientists, based on their survey of &gt;1000 scientists.

The COVID-19 pandemic is a unique situation for lab scientists, many of whose work has come to a standstill. Hamid Ghanadaan, CEO of Linus, discusses the impact of COVID-19 on science and the next steps for scientists, based on their survey of &gt;1000 scientists.

CRISPR Office Hours with Hamid Ghanadaan

What is the process to make a science film? In this episode, Sarah Goodwin and Elliot Kirschner, producers of Human Nature, a documentary on CRISPR, offer glimpses into making of the film.

What is the process to make a science film? In this episode, Sarah Goodwin and Elliot Kirschner, producers of Human Nature, a documentary on CRISPR, offer glimpses into making of the film.

Making of a CRISPR Film: Behind the Scenes with Producers of Human Nature

Only podcast dedicated to CRISPR. Great topics and great guests. Keep it up!!

CRISPR Cuts is the best!

Perfect snippet to learn about gene editing.

Great content

CRISPR Cuts

Bill Skarnes

Dr. Bill Skarnes, Professor at The Jackson Laboratory, chats about how CRISPR edited stem cells are becoming a gold standard to study gene function and disease modeling. 

Dr. Bill Skarnes, Professor at <a href="https://www.jax.org/research-and-faculty/faculty/research-scientists/william-skarnes" rel="nofollow" target="_blank">The Jackson Laboratory</a>, chats about how CRISPR edited stem cells are becoming a gold standard to study gene function and disease modeling.

The Potential of CRISPR Editing in Stem Cells: An Interview with Bill Skarnes 

Shondra Miller

Shondra Miller shares her experience of starting a shared genome engineering resource at the St. Jude Children's Research Hospital. Learn more about her research projects and her views on the past, present, and future of the genome editing field in this podcast episode.

Shondra Miller shares her experience of starting a shared genome engineering resource at the St. Jude Children's Research Hospital. Learn more about her research projects and her views on the past, present, and future of the genome editing field in this podcast episode.

Leading St. Jude's Genome Engineering Capabilities: A Chat with Shondra Miller

Rebecca Shapiro

Rebecca Shapiro, Assistant Professor at the University of Guelph, talks about CRISPR genome editing in fungal pathogens to understand their disease-causing mechanism. Her lab also works on gene drives in fungi for studying large scale genetic interactions and developing ways for treating fungal biofilms.

Rebecca Shapiro, Assistant Professor at the University of Guelph, talks about CRISPR genome editing in fungal pathogens to understand their disease-causing mechanism. Her lab also works on gene drives in fungi for studying large scale genetic interactions and developing ways for treating fungal biofilms.

CRISPR in Fungi: An Interview with Rebecca Shapiro

Andre Watson, CEO of Ligandal, talks about how his company is improving the payload delivery of gene therapy, making it more accurate and efficient, to make new gene therapy a reality for the public.

Andre Watson, CEO of Ligandal, talks about how his company is improving the payload delivery of gene therapy, making it more accurate and efficient, to make new gene therapy a reality for the public.

Improving Targeted Delivery to Enhance Personalized Medicine

The Best Multi-Part Documentaries, with documentaries on Obama, Federer vs Nadal, the making of Star Wars, Netflix vs Blockbuster and more. Add episodes you're interested into your queue below!

Best Multi-Part Documentaries

The best podcast episodes on non-current politics. Covering topics such as universal basic income, democracy, poverty & justice and more. For anyone interested in learning more about politics that affect that world, not just now, but in the longer term. Add episodes you're interested into your queue below!